Mercados españoles abiertos en 43 mins

Bristol-Myers Squibb Company (BMY)

NYSE - Nasdaq Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
69,31+1,29 (+1,90%)
Al cierre: 4:00PM EDT

Bristol-Myers Squibb Company

430 East 29th Street
14th Floor
New York, NY 10016
United States
212 546 4000

SectorDrug Manufacturers—General
Empleados a tiempo completo30.250

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Dr. Giovanni CaforioChairman & CEO6,69MN/A1965
Mr. David V. ElkinsExec. VP & CFO3,24MN/A1968
Ms. Sandra Leung Esq.Exec. VP & Gen. Counsel3,03MN/A1961
Dr. Christopher S. BoernerExec. VP & Chief Commercialization Officer2,78MN/A1971
Mr. Rupert Vessey M.A.Exec. VP and Pres of Research & Early Devel.3,24M1,46M1965
Mr. Paul von AutenriedExec. VP & Chief Information OfficerN/AN/A1962
Mr. Timothy PowerVP & Head of Investor RelationsN/AN/AN/A
Mr. Adam DubowSr. VP, Chief Compliance & Ethics OfficerN/AN/A1967
Ms. Ann M. Powell JudgeExec. VP & Chief HR OfficerN/AN/A1966
Mr. Louis S. SchmuklerExec. VP and Pres of Global Product Devel. & SupplyN/AN/A1956
Los importes son a partir de 31 de diciembre de 2020 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.


Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; and DarwinHealth, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Gobierno corporativo

El ISS Governance QualityScore de Bristol-Myers Squibb Company, a día 1 de julio de 2021, es 3. Las puntuaciones base son Auditoría: 3; Tablero: 6; Derechos de los accionistas: 3; Compensación: 4.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.